Christopher Frazier, MD
Family Medicine · Kendallville, INNPI 1366423105
Payments from drug & device makers
Across 426 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$985
- AstraZeneca$699
- Novo Nordisk$590
- Lilly USA, LLC$434
- Boehringer Ingelheim$410
- GSK$356
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,455100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $985 |
| AstraZeneca | 36 | $699 |
| Novo Nordisk | 41 | $590 |
| Lilly USA, LLC | 28 | $434 |
| Boehringer Ingelheim | 26 | $410 |
| GSK | 28 | $356 |
| Pfizer | 21 | $326 |
| Bayer | 15 | $244 |
| Merck | 25 | $234 |
| Sumitomo Pharma America, Inc. | 8 | $175 |
| Exact Sciences | 10 | $164 |
| Astellas Pharma US Inc | 9 | $164 |
| Abbott | 9 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $133 |
| Johnson & Johnson | 10 | $128 |
| Sanofi-aventis U.S. LLC | 8 | $124 |
| Corium, LLC | 6 | $120 |
| Xeris Pharmaceuticals, Inc. | 6 | $97 |
| Amgen | 6 | $88 |
| Novartis | 5 | $81 |
| Axsome Therapeutics, Inc. | 5 | $79 |
| Amarin Pharma, Inc. | 5 | $78 |
| Shield Therapeutics Inc | 1 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| Grifols USA, LLC | 2 | $48 |
| Dexcom, Inc. | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Radius Health, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Tris Pharma Inc | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
How this compares
$6,460 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $138,120 |
| EliquisApixaban | 121 | $128,747 |
| JardianceEmpagliflozin | 107 | $118,867 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $69,064 |
| MounjaroTirzepatide | 46 | $60,289 |
| FarxigaDapagliflozin Propanediol | 43 | $54,842 |
| JanuviaSitagliptin Phosphate | 67 | $54,351 |
| RybelsusSemaglutide | 21 | $48,963 |
| XareltoRivaroxaban | 36 | $32,141 |
| TrulicityDulaglutide | 25 | $30,716 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $23,915 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $23,713 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $19,740 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $14,655 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $590 | $187,084135 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr | $410 | $145,653136 claims |
| PfizerEliquis | $326 | $128,747121 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $356 | $102,502151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $434 | $91,00571 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort | $699 | $68,64685 claims |
| MerckJanuvia | $234 | $54,35167 claims |
| Johnson & JohnsonXarelto | $128 | $32,14136 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $175 | $7,18614 claims |
| Astellas Pharma US IncMyrbetriq | $164 | $7,13014 claims |
| AbbVieSynthroid | $985 | $4,67879 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Kendallville
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.